Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Kantor

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Journal of the Neurological Sciences|December 17, 2015
Demonstration of equivalence of a generic glatiramer acetate (Glatopa™)James Anderson, Christine Bell, John Bishop, et al.
Journal of Pharmacy Practice|August 30, 2017
Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple SclerosisChristine Bell, James Anderson, Tanmoy Ganguly, et al.
Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Neurology|November 14, 2024
Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic IndicationsCarson M Quinn, Prashanth Rajarajan, Alexander J Gill, et al.
Neurology. Clinical Practice|May 1, 2018
Effectiveness of alternative dose fingolimod for multiple sclerosisErin E Longbrake, Daniel Kantor, Siddharama Pawate, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of the Neurological Sciences|December 17, 2015
Demonstration of equivalence of a generic glatiramer acetate (Glatopa™)James Anderson, Christine Bell, John Bishop, et al.
Journal of Pharmacy Practice|August 30, 2017
Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple SclerosisChristine Bell, James Anderson, Tanmoy Ganguly, et al.
Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Neurology|November 14, 2024
Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic IndicationsCarson M Quinn, Prashanth Rajarajan, Alexander J Gill, et al.
Neurology. Clinical Practice|May 1, 2018
Effectiveness of alternative dose fingolimod for multiple sclerosisErin E Longbrake, Daniel Kantor, Siddharama Pawate, et al.
Pageof 3